Review on

Yellow Fever: The Current Understanding of Epidemiology, Transmission, and Prevention

[In the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy]

Submitted To

The Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

Submitted By

Student ID:191-29-222

Batch: 21PC (C)

Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

April 2023

APPROVAL

This project paper, **"A review on Yellow Fever: The Current Understanding of Epidemiology, Transmission, and Prevention",** submitted to the Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, has been accepted as satisfactory for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy and approved as to its style and contents.

BOARD OF EXAMINERS

……

Dr. Muniruddin Ahmed

Professor and Head,

Department of Pharmacy,

Faculty of Allied Health Sciences,

Daffodil International University

…… Internal Examiner 1

……. Internal Examiner 2

…… External Examiner 3

Md. Sadman Hasib

Lecturer

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

DECLARATION

In accordance with the Bachelor of Pharmacy (B. Pharm) Degree Requirement, I thus declare that I'm conducting this thesis work under the guidance of Md. Sadman Hasib, Lecturer, Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University. I, therefore, state that this project is entirely my original work. I further declare that neither this thesis nor any portion of it has been submitted for the bachelor's award or any other degree outside of the university.

Supervised By

Md. Sadman Hasib

Lecturer

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

Submitted By



Jahanara Afrin Sanzida

ID: 191-29-222

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

ACKNOWLEDGEMENT

I might want to communicate my profound applause to the All-powerful Allah who has given me the capacity to finish my undertaking work and the chance to concentrate in this subject.

I'm a lot of thankful to my honorable project supervisor of **Md. Sadman Hasib, Lecturer**, Department of Pharmacy, Daffodil International University for her brilliant direction and steady oversight just as for giving essential data in regards to the task and furthermore for her help in finishing the project.

I would like to express my humble regards to Dr. Muniruddin Ahmed, Professor and Head, Department of Pharmacy, Daffodil International University.

I also wish to offer my respect to all of the teachers of Pharmacy Department, Daffodil International University and thankful to other members for their excellent cooperation with us.

Finally, I would like to express my gratitude towards my parents and other family members for their kind cooperation and encouragement which helped me in completion of this project.

My Parents

The persons who always encourage me in every sphere of my life.

Abstract

In many regions of the world, outbreaks of the viral disease yellow fever continue to be a source of worry for public health. Yellow fever epidemics have continued and spread into new regions in recent years despite the widespread availability of an extremely effective vaccine, making many communities vulnerable. The epidemiology, transmission, as well as prevention of yellow fever are discussed in this review paper, with an emphasis on the value of immunization, vector control, efficient monitoring, and outbreak response tactics. The epidemiology of yellow fever is reviewed, along with the disease's global spread, modes of transmission, and at-risk populations. We investigate the different ways that yellow fever is spread, such as mosquito-borne dissemination and human-to-human transmission. The methods for avoiding and managing yellow fever are described, and the difficulties encountered in doing so are examined. A greater understanding of the etiology of yellow fever as well as the creation of fresh vaccines and treatments hold hope for the disease's prevention and treatment. We may work toward a future when yellow fever poses no threat to world health by continuing to expand on our existing understanding of the illness.

Key words: Yellow fever virus, diagnosis, treatment etc.

Contents

List of figures

List of tables

Chapter 1
Introduction

1. Introduction:

The Americas and Tropical Africa are primarily affected by the viral disease known as yellow fever. The disease-causing flavivirus, which belongs to the Genus flavivirus and derives from the Latin for "yellow," "flavus," is contagious. Mosquito vectors that spread yellow fever include Aedes species in Sabethes, Africa and Haemagogus and species in South America. A single-stranded, positive Genetic code makes up the virus that ranges in length from 10,500 to 11,000 nucleotides. In 1927 a male patient was the first to have the virus discovered. [1]. Yellow fever infection can cause symptoms ranging from a mild flu-like illness to severe liver disease and hemorrhage after a 3-to-6-day incubation period. Fever, headache, jaundice, muscle pain, nausea, vomiting, and fatigue are all possible symptoms. Approximately 15% of the population infected through mosquito bites develop severe symptoms, with case fatality rates ranging from 20% to 50% [2]. Most cases of yellow fever occur in 32 African countries, including Rwanda and Sierra Leone, and in 13 Latin American countries such as Bolivia, Brazil, Colombia, Ecuador, and Peru [3]. In contrast to South America, yellow fever infection rates are higher in Africa because the epidemiology of the disease incorporates both enzootic and domesticated vector species. In thepast, yellow fever posed a serious threat to human health, generating recurrent epidemics in coastalcities and villages all over the world, especially in the Caribbean, North America, and Europe. Anunusual yellow fever transmission in Asia was seriously threatened by the repatriation of 11 sick employees from Angola to China in 2016 [4]. The danger of transmission of disease has grown because of more trade and tourism between China and Africa. In Asia, the yellow fever virus, which is common in Africa and South America, has not yet been discovered. The absence of a sylvatic cycle [7,8] in conflict with existing flaviviruses like Japanese encephalitis viruses and dengue as well as factors like small period and low viraemia in humans, are the main causes of this absence, which makes an epidemic unpredictable [9].The increased presence of *Aedes aegypti*and the replacement of Aedes albopictus in Asian cities has resulted from ecological disruptions caused by urban habitats [10]. In East and Southeast Asia, Aedes spp. mosquitos, which are also vectors for chikungunya, dengue, and Zika viruses, provide a favorable environment for YFV.

1.1 History:

The term "yellow fever" is thought to have been coined in the 17th century to describe the disease's common symptom of skin yellowing[11]. However, the first documented account of a yellow fever outbreak was written during the 1793 epidemic in Philadelphia by Benjamin Rush. Griffin Hughes is thought to have coined the term "yellow fever" in his 1750 book, Natural History of Barbados. A Cuban scientist named Carlos Finlay was the first to discover in the late 1800s, mosquitoes were the main source of yellow fever transmission. Carlos Finlay made several attempts to validate his theory but was unsuccessful. But when Aristides Agramonte, Walter Reed, Jesse Lazear James Carroll, were sent to examine the origin of yellow fever in the late 1800s in Cuba, their research was based on his findings.. During its war with Spain, the United States attacked Cuba, 13 soldiers contracted yellow fever for everyone who perished in combat. The crew was sent to Cuba by Surgeon General George Sternberg, and Reed's investigation eventually determined that Aedes mosquitoes were the main source of illness transmission. Furthermore, according to his findings, a filterable chemical present in the blood of infected people is what causes yellow fever. Yellow fever was thought to have begun in Africa and traveled to the Americas and Europe via the slave

trade. [12]. In Yucatan, Mexico, in 1648, there was the first reliably identifiable reported breakout of yellow fever [13]. Tropical areas of Central and South America, along with port towns in both Europe and North America, were devastated by yellow fever outbreaks from the 18th to the 19th centuries, with descriptions of outbreaks dating back to 1495 in Haiti [14]. Cities like Philadelphia, New Orleans, and Norfolk were affected by the illness, which caused significant harm and resulted in the deaths of 5,000 people in Philadelphia during the 1793 outbreak [15]. About 25% of Rio de Janeiro's population perished from yellow fever during the outbreak in Brazil in 1850 [16]. With a mortality rate of 50–60% among those infected, the 1853 New Orleans outbreak resulted in over 8,000 fatalities [17]. Tens of thousands of people died as a result of a significant outbreak of the disease in Cuba in 1871 [18]. European nations were also affected by yellow fever; outbreaks were noted in Swansea, Wales, and Dublin, Ireland. More recently, in 2016, there was a significant outbreak in Angola that resulted in over 7,000 suspected cases, 400 fatalities, and spread to other nations, including China [19]. With over 1,500 confirmed cases and more than 550 fatalities in 2017, Brazil experienced another significant outbreak of yellow fever, prompting a broad vaccination campaign [20].

1.2 Epidemiology of yellow fever

1.2.1Geography:

The distribution of YFV's mosquito vectors is a direct reflection of its epidemiology. Large quantities of human serum from native African populations were examined to determine YF endemic places at an earlier time between the 1930s and 1940s before YF immunization became widely employed. Forest workers in South America should get immunized because yellow fever is still a risk there. However, due to the presence of Aedes aegypti mosquitoes, there is growing concern that yellow fever could trigger violent outbreaks in urban areas of the Americas (including southern regions of the United States). In the absence of a sylvatic cycle, epidemic urban YF has been eradicated from cities in North America and Europe thanks to better sanitation and mosquito control initiatives. Its most recent epidemic was in 1905 in New Orleans. Around 200,000 people are still expected to be affected by YF in tropical regions of Africa, Latin America, and Central America, with at least 30,000 mortality annually [21]. In a bid to prevent the disease's spread, many countries demand confirmation about yellow fever vaccination upon arrival or departure. In order to create effective prevention and control strategies, public health officials and travelers must understand the geographic distribution of yellow fever.

1.2.2 Africa:

A report by the World Health Organization (WHO), the YF transmission zone in Africa extends around 15° south and 15° north of the Equator and comprises 32 Sub-Saharan African countries ranging from the Sahara desert's southernmost tip to Angola. (Figure 1).

Figure 1: This image depicts the shaded areas that indicate the Yellow fever endemic zone in Africa, and it was adapted from World Health Organization maps to represent this information [22]

During widespread YF vaccination operations, Francophone West Africa gave about 40 million doses of FNV between 1940 and 1953, virtually eliminating YF in the area. Yet, in nations lacking immunization programs, YF continued to be an endemic illness with sporadic outbreaks [23-25]. Because there were fewer instances reported, interest in YF waned in the latter portion of the 1950s, neglecting surveillance and immunization campaigns as a result. In response to reports of serious and deadly encephalitis in kids below the age of 12 who got the vaccine [26], FNV manufacture and use were halted After the end of the large immunization drives, YF epidemics returned throughout Francophone West Africa within five years. Due to the discontinuation of widespread immunization campaigns for the YF virus in Africa since the 1960s, children under the age of 15 have been the primary victims of current epidemics [27,28]. Between 1965 and 1991, children made up 62% of all YF cases that were reported in Africa, with Senegal, Burkina Faso, as well as Cameroon accounting for more than 80% of all child YF cases. Only five of the 41 YF outbreaks in Africa between 1983 and 2003 were in central and eastern Africa. While significant numbers of non-immune inhabitants move into YF endemic areas during times of war or civil disturbance, YF epidemics in these areas frequently follow, as was the case with the YF breakout in the Nuba mountains near Sudan around 1940.With over 20,000 cases and 4,000 deaths between 1984 and 1993, Nigeria reported the most cases. In 1994, an outbreak in Nigeria also spread to nearby Cameroonian regions. With 83% of cases reported to the WHO between 1965 and 2004 occurring in Africa, YF cases and epidemics are more severe in that continent than in South America. Despite the size of the YF endemic zone in Africa, not all regions are equally affected by cases and epidemics. Among the 34 outbreaks between 1985 and 2005, 29 were reported from West Africa. It's common for epidemics to occur in East and Central Africa during periods of unrest, as was the case with the outbreaks in Ethiopia in the 1960s and 1962 and more recently in

Sudan in 2003 and 2005.West Africa, in contrast, does not experience epidemics due to large-scale human migrations into regions with endemic diseases. Nearly 1 million doses of yellow fever vaccine were distributed through mass immunization campaigns supported by the WHO and other donors in an effort to contain the outbreak. For travelers and public health officials, it is crucial to understand the distribution of YF when developing prevention and control strategies [29]. Recent research has suggested both genetic and behavioral differences among YF mosquito vectors may affect their vector competence. Unfortunately, there has been little research comparing vector populations in Africa's YF endemic zone, making it impossible to completely understand the role of mosquito vectors in the development of YF.

1.2.3 South America:

The Amazon, Orinoco, and Araguaia River basins in South America have the highest rates of yellow fever (YF) activity, with sporadic reports from nearby areas like Trinidad. There are 160 forest YF cases recorded on average in South America yearly, with such a 65% rate of fatalities. Significant YFV circulation occurred in Brazil's Pará as well as Goiás states from 1997 through the inaugural decade of this century. It later spread to areas in the nearby Mato Grosso do Sul states and Goiás and regions like Argentina and Paraguay, where YFV circulation had not been detected for 34 as well as 41 years, respectively. Colombia and Peru, both endemic countries, have reported numerous outbreaks, with the latter accounting for nearly half of all YF cases reported in the Americas [30]. Vaccination is a crucial strategy for outbreak control, and recent effective immunization efforts have reflected in a drop in human cases. The majority of YF cases are found in Brazil's Amazonian and central-western areas. In 1949, a campaign to eliminate Aedes aegypti was developed by ten tropical Latin and South American nations, including Peru, Bolivia, Guyana, Brazil, Panama, Colombia, French Guiana, Ecuador, Suriname, and Venezuela. The effectiveness of this initiative led to the eradication of the mosquitoes from urban areas, eliminating urban YF transmission. [31].

Figure 2: Zones shaded on modified WHO maps represent the yellow fever endemic areas in South America. [32].

As of November 1995, nearly 200,000 cases of dengue fever, a viral infection spread by Aedes aegypti mosquitoes, have been documented across 27 South American nations, the Caribbean and the Central America. [33,34]. An entomological investigation conducted during an epizootic wave in the Iju River watershed discovered a significant minor rate of infection (MIR) of 3.70% for YFV in H. leucocelaenus. [35]. This study also showed that Aegypti serratus, a previously unexplored possible vector, carries YFV around 50 km of Porto Alegre, Brazil's state capital. There are approximately 3.5 million people in the Porto Alegre metropolitan area who are not immunized against yellow fever. The case fatality rate (CFR) for the outbreak in 2008 was estimated to be 43% [36].

1.2.4 Europe:

Europe has been the only region free of YF outbreaks ever since 1861 breakout near Saint Nazaire, France, carried in by a made of wood sailing ship from Havana. Before docking in Saint-Nazaire, the ship, designated "Anne Marie," had such a case rate of death of 22% due to YF. Nonetheless, since 1979, there have been cases of YF immigration to Germany, Spain, Switzerland, France, the Netherlands, and Belgium, most often by unvaccinated tourists coming through YF endemic regions in South America and Africa [37-41].

Chapter 2
Purpose of the study

2.1 Purpose of the study:

1. The project aims to comprehend the epidemiology of yellow fever.

2. The primary objective is to create reliable and effective vaccines and treatments to safeguard individuals against yellow fever.

3. The project seeks to enhance disease surveillance and response for improved control and management of yellow fever outbreaks.

4. A further objective is to assess the social and economic effects of yellow fever breakouts on the affected populations.

5. The goal of the study is to increase our understanding of the genetic makeup and reproduction of a yellow fever virus.

6. The project aims to enhance the capability to prevent and control outbreaks and decrease the burden of yellow fever on affected populations.

7. The project also seeks to improve vector control measures to reduce the population of mosquitoes that transmit yellow fever.

Chapter 3
Methodology

3.1 Methodology

Introduction: This study is based on a thorough review of the literature, with findings drawn from approximately 45 papers.

Research design: This investigation was conducted using Google Scholar and several websites to gather relevant literature.

Data Collection: Data was gathered for this review from a variety of sources, including scholarly articles and online resources, in order to document the effects of various treatments.

Chapter 4
The Yellow Fever Virus

4.1 Microbiology of yellow fever virus:

The YF virus is indeed an arthropod-borne virus called "arbovirus," and is the prototypical species of the Genus flavivirus of the Flaviviridae family. This phrase refers to a wide group of viruses transferred between vertebrate hosts by arthropods. Monkeys and humans are the hosts of the YF virus, and mosquitoes of various kinds transmit it [42,43]. The Flaviviridae family contains around 70 viruses, the majority among which are arthropod-borne. Dengue viruses as well as Japanese encephalitis virus are two more significant diseases in this family. YF virus is antigenically linked to Zika, Banzi,Wesselsbron, Bouboui as well as Uganda S virus, each of which belongs to Flaviviridae family members native to Africa[44]. It is essential to research the virus's cellular and molecular structure, reproduction, and pathogenesis if one wants to comprehend the microbiology of YFV.

4.1.1 Virion structure:

The enveloped yellow fever virus (YFV) seems to have a dimension of around 50 nanometers. It is made up of a lipid envelope produced from the cell membrane of the host and a nucleocapsid which completely covers the viral RNA genome. Protein spikes formed of the viral surface proteins are present on the envelope's surface. The E binding protein, which is a major part of the virion membrane [45]. and is in charge of specific receptors, virus particles formation, fusion function at acidic condition, and immunogenicity [46]. The YFV's approximately 11 kilobases long RNA genome encodes for just a polyprotein that is separated into three protein molecules (the head, precursor barrier, as well as envelope) and seven nonstructural proteins. The 5' terminal of the genome features a cap structure. The genome possesses the cap structure just at 5' end but also has 3' final polyadenylation [47]. The stem-loop pattern that the 3' end nucleotides produce aids in genome stabilization and serves as a cue for the start of translation as well as RNA synthesis. [48]. The viral proteins are generated as polyproteins and transcribed in an unique open reading frame before being broken down by proteolytic cleavage. The structural proteins (C, M, and E) generally located in the 5' quarter of the genome, whereas the nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, as well as NS5) that make up the viral replicase are encoded in the last four of the genomes. [45,47].



Figure 3: The yellow fever virus virion [49].

4.1.2 Virus replication:

When they infect cells, flaviviruses like YFV have just ten proteins at the cellular scale (Figure 4). Yet, the technique by which the virus interacts with the human host is intricate. The virus has developed the ability to make use of the host's macromolecular synthesis machinery in order to promote viral replication and evade antiviral defenses [50]. These viruses manipulate key stages in their life cycle pattern detection receptor, stress granules, and membrane structures to do this. To find weak spots in the viral amplification cycle, researchers are trying to understand the molecular mechanisms underlying these activities. These flaws could be taken advantage of to create potent vaccine candidates or create antiviral medications.



Figure 4: The yellow fever virus genome [51].

The E glycoprotein changes shape in the endosome's acidic environment. This change makes it possible for the nucleocapsid to be released into the cell's cytoplasm by fusing with endosomal membrane and releasing the viral lipid envelope [52,53]. The genome is then instantly translated once the nucleocapsid disassembles, and replication continues. 50 to 30 possible secondary structure sequences are discovered in the genome as two short and conserved repetitions, CS1 and CS2. These final sequences' base pairing is assumed to be what circularizes the genome. This circularization process helps the translation, replication, and storage of the genome. [54].

The AUG codon towards the 50 end of the genome is where cap-dependent translation for such lengthy ORF begins 41. It is believed that the virus makes use of the host's eukaryotic translation starting factors (eIFs), which include membrane-bound ribosomes, members of the eIF4F complex, and many other protein. It is noteworthy that in some circumstances In order to compete with recipient mRNA translation, flaviviruses may potentially employ a unique cap-independent translation method. [55]. The closely controlled progressive fragmentation of the protein complex into distinct mature proteins is mediated by proteases produced by the recipient and the virus [45,50,56]. After already being translated and processed, the viral NS protein come together to create the replicase. When this replicase recognizes the secondary structure within the 30 terminals of the genomic RNA, it starts making complete copies of negative sense RNA from the genomic template utilizing the NS5 RdRp. Positive-sense RNA genomes are created as a result of the quick transcription of these negative-sense RNAs. During non - symmetric RNA replication, positive-strand synthesis is significantly more efficient than negative-strand synthesis. This may be due to the different stem-loop frameworks at the 30- terminal end points of both the positive and the negative strands, which may have an impact on the reproduction complex's ability to initiate replication. [54].

The timeframe of YFV RNA production varies depending just on virus strain and cell type, with detection occurring 3 to 6 hours after contamination and the release of progeny virions taking place approximately 12 hours later. In the ER, immature and healthy viral particles gather, where the C protein forms a complex with viral RNA as well as the ER-derived lipid bilayer contains prM and E protein heterodimers [57,58]. It implies that intracellular budding happens via the host cell membrane. Immature flavivirus particles are transported from cell's membranous elements to the plasma membrane by vesicles that contain virion. As these vesicles merge with the plasma membrane, the contents of the vesicle, including the virions, are discharged into the extracellular space [59]. E proteins are protected from irreversible conformational changes while being formed and transported in the acidic sections of the secretory pathway by the prM protein precursor [60]. The trans-Golgi route is where virion maturation occurs. There, a prolonged cleavage of prM into M [61,62] by furin results in alterations to the E protein that boost infectivity. Finally, exocytosis releases mature and virus particles into the extracellular media.

4.2 Virus transmission cycle:

The yellow fever virus persists in the wild by a number of mechanisms, including vertical transmission in skilled vectors, horizontal transmission via blood-feeding mosquitoes, and transmission between non-human primates (NHP). The three stages of the virus' transmission to humans are sylvatic, intermediate, and urban. (Figure 3) [63]. Yellow fever's natural epidemiology involves the virus cycling among rainforest mosquitoes and wild monkeys.

Yellow fever's sylvatic (forest) transmission cycle occurs in Africa and South America's tropical rainforests, where the virus is indigenous and spread by various monkey species and vectors residing in the forest canopy. The replication occurs in these animals' blood, causing serious disease or death. Symptoms of infection include lethargy, vomiting, fever and hemorrhaging. Since 1942, this method of transmission has been responsible for the majority of yellow cases reported in Latin America, and it has generally been limited to the Amazon regions. Yet, as seen in Brazil, it has the capacity to create widespread outbreaks [64,65]. vertebrate animals can catchdiseases, only primates are thought to contribute to the transmission in their natural environment.The New as well as Old Worlds' transmission cycles are different because monkeys in South America frequently contract diseases and pass away as a result, while those who live in the Old World normally show no symptoms. Howler monkey (Aloutta spp.) are thought to be a part of theYFV-transmission process in South America, where they develop a deadly illness as a result.

Yellow fever's intermediate transmission cycle causes small-scale epidemics in African savannah settlements. Semi-domestic mosquitoes carrying the virus feed on both human and monkey hosts, enabling the virus to spread. Aedes furcifer, Aedes luteocephalus, Aedes opok, Aedes taylori, Aedes metallicus, Aedes vittatus, and members of the Aedes simpsoni group are among the vectors for this cycle. [66]. The virus isn't just transferred between monkeys, as well as between humans. In Africa, a thorough description of history for Yellow Fever (YF), as well as the importance of African YFV vectors, is given in Mutebi and Barrett's most recent paper [67].

In the urban transmission, Aedes aegypti mosquitoes transfer the yellow fever virus between people. Proficient urban mosquitoes [68] can spread the virus from person to person as mosquitoes fed on individuals with elevated virus infection, permitting the virus to be passed in the saliva. This phase occurs both urban and semi-urban settings and is predicated on the virus's ability to infect and spread in Aedes aegypti, resulting in the start of unregulated outbreaks with disastrous effects [69].



Figure 5: Cycles of yellow fever transmission [70].

4.3 Pathogenesis and pathophysiology:

The YF virus has been linked both for neurotropic as well as viscerotropic diseases in a variety of vertebrate hosts. When infant mice are inoculated with the YF virus intraperitoneally or intracerebrally, encephalitis is prevalent. It ought to be highlighted, nevertheless, that the amount of neuropathogenicity varies greatly amongst viral strains[71]. The virus can also be transmitted intracerebrally to guinea pigs as well as older mice. When contracted by the peripheral route, YF infection typically in both humans and primates that are not humans (including such rhesus cynomolgus but also macaques) often appears as viscerotropism. Monkeys infected with the forest virus intracerebrally can develop encephalitis but die due to viscerotropic YF. Monkeys are very susceptible to YF, which has a 50% lethal overdose compared with fewer than 1 PFU [71]. The replication occurs and produces disease in organs such as heart, the liver, spleen as well as kidneys.

Yellow fever (YF), that can be life-threatening for individuals, has a clinical pathology that often features enlargement, obstruction, and fluid accumulation in the kidneys. Futhermore, the heart is frequently enlarged. The liver, the typical organ injured by YF, looks pretty normal or slightly enlarged as well as discolored from jaundice, and with telltale lobular structures gone [72]. The centre of the liver lobule's hepatocytes are enlarged and cell death under a microscope, whereas cells around the central veins and in the portal region are unscathed. Councilman bodies, a disorganized midzonal hepatocyte plate, and a deposition of microvesicular lipid are all recognized as common characteristics of catastrophic YF [73,74] Immunocytochemistry as well as nucleic acid hybridization are used to identify the viral antigen and RNA that are linked to the pathologic

alterations [73,74].Apoptosis causes cell death after direct viral damage [75].Interestingly, there is little to no inflammation, and individuals with YF-associated hepatitis who recover do not experience cirrhosis or long-lasting scarring. The existence of YF antigens inside the tubular cells of the kidney in deadly human cases shows that the virus damages these cells directly. In monkeys, however, renal tubular function is preserved throughout the disease.



Figure 6: Yellow fever pathogenesis as studied in experimentally infected monkeys as well as human case reports [71].



Figure 7: The histopathological characteristics of yellow fever infections of the liver [71]

Test is performed in YF is characterized by pre-renal failure with hypotension, while acute tubular necrosis becomes usually fatal [76]. The appearance of yellow fever antigens in glomerulae 2-3 days following the infection of monkeys, as well as histological changes in the membrane as well as cells lining Bowman's capsule, indicating that the significant albuminuria in YF may be attributable to variations in glomerular function. In the final stages of the illness, hypotension and shock are probably triggered by cytokine dysregulation, which has been associated with VHFs and bacterial sepsis. TNF and many other cytokines manufactured by highly infectious Kupffer cells as well as splenic macrophages in responding to straightforward virus damage and the cytotoxic T cells associated in viral clearance may cause cell damage, oxygen production from free radicals, endothelial dysfunction, microthrombosis, distributed intravascular clotting, cellular anoxia, oliguria, and astonishment. To discover the cytokine regulators of the shock syndrome, more research on sufferers or experimentally infected animals is required [71].

It is believed that diminished blood circulation, instead of direct viral infection, is what causes the acute tubular necrosis seen in the kidneys during YF. Muscle cell degeneration may be concentrated in the heart [74]. In both the lymph nodes and the spleen, there is a clear sign of B-cell necrosis [72]. Fluid overload and petechial hemorrhages in the brain are possible, but viral infiltration and encephalitis are uncommon. Reduced liver production of clotting factors, which results in disseminated intravascular coagulation, is the main cause of bleeding during YF (DIC). Increased levels of both pro and anti-inflammatory mediators [77] during acute YF are closely linked to hemorrhagic symptoms and catastrophic outcomes, suggesting they play a role in the development of the illness. While hepatocytes [75], endothelial cells [78], and activated macrophages [79] could be involved, the origin of cytokines is still unknown.

4.4 Clinical manifestations:

Yellow fever's clinical manifestations vary greatly and fall into one of four main phases:

Phase of infection: This phase is defined by a 3–6-day-long viremia period. While some cases show no symptoms at all, others do so and present with flu-like symptoms such fever, chills, headache, muscle pain, appetite, nausea, and vomiting.

Phase of remission: Three to four days after the onset, patients go through a 12 to 24-h cycle of recovery, during which the majority of symptomatic patients feel better and their symptoms go away. Yet, within 48 hours, 15% to 25% of sufferers relapse with symptoms and go into the toxic phase.

The toxic phase, also referred as the phase of the kidney and liver injury, lasts for three to eight days. Patients begin to exhibit increasingly severe symptoms at this time, including high fever, jaundice, internal bleeding as well as multiple organ dysfunction affecting the liver, kidneys, and blood system.

Chapter 5
Diagnosis and Treatment

5.1 Diagnosis:

The shortcomings in surveillance and diagnosis capacity have been emphasized by several authors. Due to the lack of accurate diagnostics, these deficiencies, which exist in both endemic as well as non-endemic countries, can cause a delay in the detection of an outbreak. For every serious case, there could be up to 70 silent or mild infections, according to Johansson [80] as well as his colleagues. Yellow Fever (YF) observation monitoring illness incidence is essential for early outbreak discovery and the deployment of control measures. Case reporting is required by the Global Health Regulations in order to help forecast and manage epidemics. For quick reaction and epidemic control, emergency vaccination efforts are essential, although underreporting is still a significant issue. Approximately 250 times additional cases than those documented are thought to exist. An outbreak is defined as one confirmed incidence in an unvaccinated population, and one such case necessitates a full investigation. Any confirmed case merits examination, even in locations where vaccination is widespread. Rapid emergency action must be taken, and long-term immunization strategies must be created by response teams.

5.1.1 Clinical diagnosis:

Yellow fever (YF) should be assumed to be present in people living in endemic regions or who have traveled there frequently and have a high fever, substantial bradycardia, and signs of jaundice. To confirm the diagnosis, a complete blood count, urinalysis, liver function tests, coagulation tests, viral blood cultures, in addition to serologic tests, must be performed. Typical findings in YF include leukopenia with relative neutropenia, thrombocytopenia, prolonged clotting, and higher prothrombin time. Acutely elevated levels of aminotransferase and bilirubin may last for several months. YF can be distinguished from other types of hepatitis thanks to albuminuria, which is found in 90% of patients.

Due to the different levels of symptom intensity and clusters, identifying YF in the field—especially in isolated cases—can be difficult. Jaundice may not always present in mild instances, and YF is frequently confused with other illnesses such Lassa fever, Dengue fever, malaria, Ebola fever, typhoid, hepatitis, & poisoning. The differential diagnosis of individuals who present with symptoms including nausea, headache, backache, and fever, particularly at the beginning of the infection, may not include YF even though classic instances should be simple to identify.

Table:1
Investigation in the lab for possible yellow fever

CBC count	• relative neutropenia and leukopenia • Consumptive coagulopathy-associated thrombocytopenia • Early hemoconcentration with higher levels of hematocrit and hemoglobin • Hemorrhage and hemodilution that follow, along with a decline in total blood cell counts
Coagulation analyses	• decreased levels of coagulation factors II, V, VII, VIII, IX, and X and fibrinogen • fibrin split products are present, which indicates diffuse intravascular coagulation. • decreased production of clotting factors • Prothrombin time increase • prolonged time for clotting
Urinalysis	• elevated amounts of urine protein • increased amounts of urobilinogen
Liver function tests	• Transaminitis begins with jaundice, and the degree of cirrhosis of the liver during the first stage may be a strong predictor of the clinical course.. • Alanine transferase levels are lower than serum aspartate transferase levels. • increased amounts of direct bilirubin

5.1.2 Laboratory diagnosis:

Yellow Fever (YF) diagnosis requires accurate laboratory confirmation; unfortunately, this procedure can only be completed by highly qualified laboratory personnel who have access to specific tools and supplies table 2.

Any of the laboratory requirements listed below can indicate a YF diagnosis: (1) YFV isolation; (2) YFV presence; (3) positive post-mortem liver histopathology; (4) immunohistochemistry for the detection of YFV antigen in tissues; (5) polymerase chain reaction for the detection of YFV genomic sequences in blood or organ systems; or (6) the presence of YFV-specific IgM or merely a 4-fold or higher increase in IgG levels between many severe as well as convalescent serum samples with in absence of recent vaccination. Sadly, if YF is ever diagnosed at all, it is frequently discovered after the sufferer has either healed or passed away. A suspected case of YF is defined by the rapid rise in temperature followed by the development of jaundice within 2 weeks after the onset of the initial symptoms. A laboratory diagnosis of YF is necessary, or there must be an epidemiological connection to an epidemic or patient that has received a laboratory diagnosis.

Table:2
Tests in a laboratory for diagnosis

Serologic/immunologic	• An enzyme-linked immunosorbent assay (ELISA) is used to identify YFV-specific IgM, while in the absence of current immunization, a single adequate serum titer is diagnostic. • An increase of four times in YFV-specific IgG antibodies in someone who has not recently had vaccinations • Cross-reactivity with some other flaviviruses must be ruled out, frequently by probability of exposure • lesions that resemble YF lesions or immunohistochemistry staining used to find virus in tissue. Due to the increased risk of bleeding, liver biopsy is frequently performed post-mortem.
Molecular	• Reverse transcriptase-polymerasechain of events for the detection ofinfectious genomic RNA in tissue, blood, or other body fluids.

	• YFV antigen detection in serum samples

5.2 Prognosis:

Younger people often have a better prognosis than older ones, and those in excellent health have a higher probability of recovering than those with immune systems that are compromised or other medical disorders. Yellow fever outcome is depending on a variety of circumstances. While mild symptoms of yellow fever typically go away in a few days to a few weeks with rest, supportive care, and medications to lower fever, severe cases can cause life-threatening complications like liver and kidney malfunction, losing blood, and shock, with the significant portion of fatalities taking place within the first ten days after being ill. The number of fatalities for yellow fever differs based on the epidemic and community affected; in severe outbreaks, the mortality rate might reach 50%, especially in populations that have not had vaccinations. The death rate is substantially lower, often about 1%, in regions wherever yellow fever vaccination has widely practiced. The prognosis can also be influenced by the illness's severity, with mild cases often having no long-term repercussions and severe cases possibly resulting in organ damage, shock, or perhaps even death. Yellow fever could be avoided with a highly efficient immunization. Additionally, early detection and treatment can assist patients who get the condition have a better prognosis. It is critical to seek quick medical assistance for a diagnosis and treatment if someone exhibits yellow fever symptoms, especially if they have recently been to an area where the disease is endemic [81].

5.3 Management:

Vaccination: The most effective method of preventing yellow fever is vaccination. Long-lasting immunity is provided by the extremely effective and safe yellow fever vaccination. It is advised for people visiting regions where the disorder is endemic in addition to those who stay in or close to such regions.

Mosquito control: Controlling mosquitoes is crucial in halting the development of yellow fever. Insect repellents, protective clothing, and mosquito netting can all help you do this. Also, it's crucial to get rid of any standing water around residences and neighborhoods because this is where mosquito develops.

Early identification and diagnosis: Yellow fever must be identified and treated as soon as possible in order to stop the disease from spreading. Patients who have been to endemic regions and exhibit fever or other indications should be tested for yellow fever, as healthcare professionals should be knowledgeable of the disease's signs and symptoms.

Supportive care: The huge percentage of yellow fever cases are mild, and they can be controlled with measures including rest, fluids, and painkillers. Severe yellow fever patients may need to stay in the hospital for close observation and supportive care.

Complication avoidance: Serious complications can be avoided and outcomes enhanced by prompt identification and management of complications include hemorrhage, organ failure, and shock.

Governments and health organizations in endemic regions should put monitoring and control measures in place to keep tabs on and rein in the development of yellow fever. Public health initiatives, mosquito control programs, and immunization efforts may all fall under this category.

5.3.1 Pharmacological management:

Pain reliever: Common signs of yellow fever include a fever, headache, as well as muscle soreness. Pain relief may be obtained by administering over-the-counter painkillers like paracetamol or non-steroidal anti-inflammatory medications (NSAIDs).

Intravenous fluids: Yellow fever frequently leads to dehydration, which may require the administration of iv fluids to avoid or treat the condition.

Oxygen therapy: Yellow fever can cause severe breathing problems, and oxygen therapy might well be needed to help them breathe.

Blood transfusions: Due to severe cases of bleeding disorders, blood transfusions may occasionally be required.

Antiviral therapy: Although though there isn't a specific antiviral drug for treating yellow fever, in severe situations, drugs such ribavirin or interferon which have been employed to cure other Flavivirus infection may be used

5.4 Treatment:

Although intensive care may benefit patients, case fatality rates for individuals with YEL-AVD and a limited number of tourists who got the illness after returning to the United States or Europe have varied from 50 to 100%. This suggests that the result of this serious infection has not been significantly impacted by intensive care. There are currently no antiviral medications that have received formal approval for the treatment of YF, although it is likely that early initiation of antiviral medication, if produced, could be effective against the condition.

5.4.1 Passive antibody:

Yellow fever virus (YFV) has previously been treated with passive antibody treatment, particularly during epidemics. This treatment involves the delivery of YFV antibody to affected patients, which could also effectively destroy the pathogen and restrict its dissemination. According to studies, if taken within 1-3 days of being exposed to the virus [82], antiserum made in horses, monkeys, and chimpanzees can protect rhesus monkeys against the deadly effects of YFV.

Passive immunotherapy, however, has only weak clinical support for the management of YFV. One case study described giving a patient suffering advanced hepatorenal failure brought on by yellow fever a mouse monoclonal neutralizing antibody, but it failed to show any positive results

[83]. According to the knowledge that is currently available, antibody therapy, such as antiviral or interferon inducers, is unlikely to be beneficial unless it is administered before to the development of a clinical illness or in the very early stages of an illness.

As a result, passive antibody therapy is not frequently utilized as a first-line therapy for YFV, despite the fact that severe cases still may benefit from it. The best method for managing the disease is still prevention by immunization and avoiding mosquito bites. People should see their healthcare professional for advice on vaccination as well as other precautionary measures before traveling to regions where yellow fever seems endemic.

5.4.2 Interferon and Immunomodulators:

The possibility of using immunomodulators and interferons to treat the yellow fever virus has been researched (YFV). Immunomodulators are substances that can control the immunological response to an infection, whereas interferons are found naturally proteins that can kill viral infections by energizing the immune system. Several research have demonstrated that interferons can decrease the multiplication of YFV in culture, as well as animal studies have revealed that interferon therapy can enhance life expectancies in YFV-infected animals. For the treatment of YFV in humans, interferons are used, however there is little clinical support for this. Furthermore, immunomodulators like corticosteroids have been used to treat YFV, but it is still unclear how well they work. Immunomodulators can cause the disease to worsen by stifling the immunological response.

According to the study, interferon therapy helped YFV-infected hamsters survive longer and sustain less liver damage. The findings imply that interferon- may have potential like a therapy for YFV in people, but more research is required to determine its safety and effectiveness. Nonetheless, the results offer important information about potential cures for this severe viral illness, which continues to be a huge threat to global public health.

5.4.3 Some antiviral drug:

There are currently no particular antiviral medications authorized to treat yellow fever virus (YFV). Nonetheless, a number of medications, especially ribavirin, favipiravir, and sofosbuvir, have had encouraging outcomes in preclinical investigations. Both in vitro and then in animal models, these medications have been demonstrated to prevent YFV replication.

A purine nucleoside having broad-spectrum antiviral abilities against different RNA and DNA viruses, ribavirin [84]. Using pegylated interferon, it has been shown to be successful in treating prolonged hepatitis C virus. The therapeutic effectiveness of ribavirin in curing yellow fever virus (YFV) in people is not well proven, despite its potential, and its use is not currently advised. Ribavirin has been found in several preclinical studies to be able to prevent the multiplication of YFV, but its usefulness in treating human patients is still unknown, with some studies indicating a significant limitations and others demonstrating no appreciable benefit.

Tiazofurin, a synthetic derivative of ribavirin as well as an inosine monophosphate dehydrogenase antagonist, is now in late-stage experiments for treating leukemia. However, three rhesus monkeys that had regularly received huge amounts of tiazofurin (1100 mg/m2) and a fatal dose of YF Dak1279 underwent a study. Sadly, it was discovered that the medication was ineffective at treating the infection.

In vitro tests on the YF virus or other flaviviruses as Japanese encephalitis (JE) have revealed promising inhibitory efficacy for compounds like 6-azauridine, that are antagonists of orotidine 5'-monophosphate decarboxylase. In a JE mouse model, these substances were discovered to be ineffective [85].

Iminocyclitol compounds with a deoxynojirimycin functional group have been successfully used in in vitro investigations to prevent viral emerging here on endoplasmic reticulum. In micromolar quantities, these substances have shown activity against flavi- and pestiviruses[86].

In cell culture, it has been demonstrated that the substance triaryl pyrazoline [5-(4-chloro-phenyl)-3-thiophen-2-yl-4,5-dihydro-pyrazol-1-yl]-phenyl-methanone inhibits flavivirus infection. It has also demonstrated widespread effectiveness against many other RNA viruses [87].

5.4.4 Inhibition of host gene function:

A promising strategy for antiviral therapy has been identified as inhibiting host cell enzymes. This strategy involves focusing on infected cells enzyme routes, including such kinases, which viruses use for a variety of entrance and replication-related processes. Due to the repetitive nature of these enzymes, it might be possible to block a particular host route essential for virus replication without significantly increasing toxicity. A recent study supported the possibility of this strategy for antiviral therapy by demonstrating that what a c-Src kinase antagonist (dasatinib) successfully prevented flavivirus development [88].

5.5 Prevention and control:

Two live attenuated vaccines were administered in order to stop or manage Yellow Fever (YF) outbreaks [89]. The French Neurotropic Vaccination (FNV), one such vaccine, was created in the 1930s. Dessicated mouse brain that had been injected also with French neurotropic variant of the YF virus was the subject [90]. Throughout 1939 and 1953, scarification was the method utilized to distribute the vaccine, and over 80 million people received their shots this way. As a consequence, YF practically disappeared from West African nations that spoke French [91].

In 1980, production of the French neurotropic vaccine had been discontinued [89]. The second and currently employed vaccine, the 17D vaccine, was made using infected chicken embryos and is a powerful and safe live attenuated vaccine [92,93]. This vaccine is very effective and well- tolerated and has been given to almost 400 million people over the course of 60 years[89,94].The search for a yellow fever vaccine started as soon as the virus was identified in 1927. Live viral items were the focus of later vaccine development as inactivated vaccine manufacture throughout the beginning of the twentieth century proved ineffectual. Due to the unacceptably high frequency

of side events, particularly encephalitis, the French neurotropic vaccine, that initially appeared in the 1930s and also was successful in containing the pandemic in West African countries, had been discontinued in 1982.

The source of all contemporary yellow fever vaccinations is the 17D strain. Between 1937 and 1941, the United States as well as Brazil employed two main lines of the 17D strain to produce the first yellow fever vaccines (17D-204 and 17DD) [95].The continuous serial passage technique sparked worries about the potential emergence of substrains with alarming prevalence of adverse outcomes, which gave rise to the "seed lot" vaccine production system. All vaccine lots were produced using a single sentence of the secondary seed, and the method involved the manufacture and characterization of both the primary and the secondary seed lots. The World Health Organization, also known as WHO, set uniform standards for seed lots and vaccine manufacture for yellow fever in 1957. These standards involved screening for neurovirulence & viscerotropic before use. Certain formulations of the vaccine do contain gelatin even though the vaccination doesn't really comprise any antibiotics as well as preservative like thimerosal [95].

5.6 17D Vaccine Substrains Used Today:

During 204 passages of Asibi viruses in chicken tissue, the 17D-204 vaccine variant was developed, with vaccine seeds made from passages 234–238 [96]. On behalf of the WHO, the German Robert Koch Institute created a 17D-213 substrain from of the 17D-204 strain at stage 235, and vaccine seeds are employed in passages 237 and 238. In contrast, the 17DD vaccine, which has a unique passage history than the 17D-204 strain, was made from of the Asibi virus during 195 stages in chicken cell, and also its vaccine seeds usually employed at passages 285-286. Only six vaccine producers are active at the moment on a global scale. Sanofi-Pasteur through France (Stamaril®, 17D-204), Swiftwater in the US, Institut Pasteur throughout Senegal (17D-204), Tiantan as well as Wuhan Institute of Physiological Products in the Chinese People's Republic (17D-204), Chumakov Research center of Poliovirus as well as Promoted Encephalitides inside the Russian Federation (17D-213), Bio-Manguinhos/FIOCRUZ in Brazil (17D-213), and (17DD). With WHO prequalification, the vaccines created by France, Russia, Senegal, as well as Brazil are suitable for use in global markets and immunization campaigns. In order to distribute the vaccine to the 44 middle-income and low-income nations that are vulnerable to YF epidemics in South America and Africa, WHO prequalification is a thorough assessment that makes sure the vaccine satisfies the required security and efficacy necessities to be used in vaccination programs across multiple countries. Just the domestic markets of the USA and China were served by the vaccines produced there. It is significant to emphasize that these two domestically used vaccinations are not less effective than vaccines that have received WHO prequalification but have not yet submitted applications for prequalification internationally [97-100].

5.6.1 Duration of protection:

The YF vaccine had been declared effective over ten years, however the WHO Advisory Committee Group of Experts on Immunizations as well as the World Health Conference recently modified this to lengthy coverage, resulting in the elimination of the 10-year replenishment required from of the IHR [101,102]. While there isn't any surveillance for breakout infections after

marketing, the choice to extend the length of protection was partially based on the paucity of vaccine rejections in people who had been vaccinated. Because YF neutralize antibodies are associated with safety, there is some dispute regarding if a single injection of YF vaccine will protect travelers with low neutralize antibodies who are visiting a high-risk area. Some subsets of YF vaccination recipients have been identified as having weaker immune reaction and/or lower antibody durability [102-105]. Children in Brazil who received the YF vaccine alongside the measles, mumps, as well as rubella vaccines had decreased seroconversion rates, presumably because of interference from the founder among these two live attenuated vaccines vaccinations [106,107]. In Malian and Ghanaian children, YF seropositivity decreased over time, with rates having dropped from 96.7% to 50.4% as well as 72.7% to 27.8%, including both, at numerous post-vaccination intervals [108]. Among non-endemic regions, 63.8% of YF vaccine recipients were still seropositive after ten years, with seronegative most commonly

occurring between three and twelve years after vaccination [109].The ACIP also advises 10-year supplemental doses for people who received the YF vaccine prior to transplantation of hematopoietic stem cells, laboratory personnel who handle the YFV, and visitors to high-risk locations, such as those with extended stays and regions where outbreaks are occurring [102].

5.6.2 Vaccine safety and adverse reactions:

The majority of adverse effects to the YF vaccination are minor; 10–30% of recipients report mild systemic symptoms like headache, myalgias, and low-grade fever [110]. Immediate hypersensitivity or allergic reactions, YF vaccine-associated neurologic illness (YEL-AND), as well as YF vaccine-associated viscerotropic disease (YEL-AVD) are three major adverse effects connected to the YF immunization [111].

Rash, urticaria, and/or bronchospasm are the hallmarks of immediate hypersensitivity reactions. According to reports, there are 0.8–1.8 incidences of anaphylaxis following the YF vaccination for every 100,000 doses given out. YEL-AND typically affects first-time vaccine recipients and manifests mainly meningoencephalitis, Guillain-Barre syndrome, and acute disseminated encephalomyelitis. Onset occurs 3-28 days following vaccination. YEL-AND rarely causes death, with an estimated incidence of 0.4–0.8 per 100,000 doses dispersed [111] among US travelers.

YEL-AVD is comparable to wild-type disease in that it spreads widely, frequently results in multisystem organ failure, and frequently results in death [111]. Worldwide, there have been greater than 60 occurrences of YEL-AVD recorded, all of which have been in first-time vaccine recipients with appearance of symptoms occurring 0 to 8 days following vaccination. Prevalence of YEL-AVD being Among travelers is 0.3–0.4 instances per 100,000 units of disseminated vaccination, with a case-fatality ratio of 63% [111].

5.6.3 Immune response:

The live attenuated vaccine known as the 17D vaccine gives protection from it. Respectively innate as well as adaptive immunity are triggered by the vaccine. After vaccination, pattern recognition receptor (PRRs) in antigen-presenting cells (APCs) such dendritic cells (DCs) recognize viral components, triggering the innate immune response and inducing the release of proinflammatory cytokines such interferons and interleukins. These cytokines draw immune cells to the site of the infection and encourage their differentiation and growth. It normally takes several days to a few

weeks for the adaptive immunity to the 17D vaccination to develop. The vaccination includes weakened virus particles that the immune system interprets as foreign, activating T and B cells that are specific for the antigen. While the B cells create antibodies which neutralize the virus and stop this from infecting host cells, the T cells locate and eliminate infected cells. Additionally, the vaccine induces the development of recollection T and B cells, that also remain in the skin for a protracted period of time and provide long-lasting protection against yellow fever. Vaccination against 17D results in a normal Th1/Th2 immune response. Producing cytokines, Th1 cells encourage macrophage to phagocytose and eliminate infected cells and activate cell-mediated immunity. Th2 cells release cytokines that excite eosinophils as well as mast cells, which are essential components of the immune response to parasites. They also increase the generation of antibodies by B cells. Moreover, the vaccine stimulates the development of innate immune cells, including gamma-delta T cells and natural killer (NK) cells, which are essential in the initial phases of the immunological response against viral infections [112].

5.7 Contraindications:

Yellow fever (YF) immunization is contraindicated in certain people, and they should stay away from YF-endemic regions and refrain from getting the vaccine. Healthcare professionals should provide a medical exemption to the person and tell them of the elevated risk of YF owing to immunization deficiencies as well as the preventive actions that can be implemented in circumstances when travel to endemic regions cannot be avoided.

Infants younger than 6 months:

As a result of the reasonably high occurrence of yellow fever vaccine-associated neurologic disease (YEL-AND) which has been documented in vaccinated infants in this age group, it is not advised to administer the yellow fever (YF) vaccine to infants younger than six months of age [113].

Hypersensitivity:

Those who have a record of hypersensitivity to any of vaccine's ingredients, including eggs, egg products, chicken protein, and gelatin, shouldn't receive the yellow fever (YF) vaccine. Dermal testing as well as desensitization can be taken into consideration and carried out as instructed inside the vaccine product description when vaccination is considered necessary for people who are worried regarding hypersensitivity to the vaccine

Immunocompromised individuals:

The yellow fever virus is present in the 17D vaccine in a weaker form because this is a live attenuated vaccine. Individuals who have compromised immune systems, like those who have HIV/AIDS or are receiving cancer therapy, may not even be able to establish a sufficient immunological response towards the vaccine and could be at risk of experiencing serious side effects.

Women who are pregnant or nursing:

The efficacy of a 17D vaccine during pregnancy or breastfeeding has not been thoroughly proven, and the vaccine is typically not advised for these populations unless there is a demonstrable potential exposure to yellow fever.

Serious acute illness:

It may be suggested that those who are currently ill with a serious acute illness delay getting vaccinated until they are well.

5.8 Precaution:

If a person with a health issue that makes the yellow fever (YF) vaccine a precautionary measure must travel to areas where YF is endemic, a healthcare professional can weigh the risks and advantages of vaccination. The person may be exempt from YF vaccination and given a waiver if the only justification for the vaccination is to satisfy foreign travel necessities and not because of the risk of catching YF.

Infants aged 6-8 months:

The YF vaccination is often given to children between the ages of 6 and 8 months as a safety measure. This warning is composed of two incidences of YEL-AND in newborns in this age range that have been documented.

Adults 60 years of age or older:

The YF immunization is recommended as a precaution for those 60 years of age or above because to studies showing an increase in the reporting rates of YEL-AND and YEL-AVD in this age range. Extra caution should be exercised while administering the first YF immunization to elderly travelers because YEL-AND but also YEL-AVD are commonly shown in primary vaccine recipients.

Asymptomatic HIV infection with moderate immune suppression:

For those with asymptomatic HIV infection and mild immunological suppression—defined as CD4 T-lymphocyte counts between 200 and 499/mm3 or 15–24% of total lymphocytes in children under six years old—YF immunization is recommended as a preventive. Despite the small number of observational studies that have been done, no major side events have been observed among people with mild immunosuppression based on CD4 levels after receiving the YF vaccine.

Prior yellow fever vaccination:

Unless a booster dose is necessary in specific circumstances, people who have already had the yellow fever vaccine should not obtain it again.

Travel plans:

Those who want to visit regions wherever yellow fever is common should speak with a healthcare professional to find out whether vaccination is advised and to get guidance on additional preventative measures.

Medications:

Medical professionals should be consulted before administering some drugs, including such immunosuppressants and steroids, because they may interfere with the vaccine.

5.9 Prospects for the future:

The risk of spreading YFV to vulnerable regions of the globe continues to be high, especially in urbanized areas and regions with large populations who have not received the vaccine, like the coastal regions of South America. Although though YF is a spectacular disease and would probably be identified shortly after an introduction, mass immunization of adults with the YF 17D vaccine is not advised due to the possibility of major adverse outcomes. An outbreak among susceptible populations in nations such as India as well as Southeast Asia would raise serious concerns and necessitate an immediate vaccination program. Thankfully, WHO keeps a supply of vaccines in case of emergency, although a severe shortage of supplies is still possible. Since the current vaccine products are formulated an excess of approximately 100 times the virus that is required for effective immunization, dose sparing methods could be used to address this issue [114]. If a decrease in injection volume might preserve vaccine stock while maintaining effectiveness, more clinical research is required to make that determination.

Particularly for the elderly, those who have side effects or precautionary measures, and in situations involving mass vaccination, the protection of the yellow fever (YF) vaccine remains a concern. An attenuated YF 17D vaccine has been created and clinically tested in the US [115], but due to the likelihood that it would only offer transient immunity, commercial development was not pursued. Yet, the inactivated vaccine might be strengthened with a live 17D vaccination, which would result in long-lasting reactions without any negative side effects. Brazil is currently working to create an immobilized or recombinant isoform vaccine, despite the fact that market forces might not be in its favor. These sustained efforts are required. To better understand disease pathogenesis, especially aspects that can't be acquired from human patients, experimental studies on non-human primates are crucial. Clarifying the function of systemic inflammatory syndrome (cytokine storm) inside the pathogenesis of YF, as well as the precise function of cytokines like TGF-, TNF-, IFN-, and IL-6 in the liver and other affected organs, should be prioritized, along with looking into potential interventional strategies. Such studies assist in the prospective medical management of situations of YEL-AVD in addition to assisting in the understanding of just how wild-type YFV provokes fatal outcomes. Research findings in the YF monkey model, that may be carried out under BSL3 circumstances, might shed new light on generally applicable pathophysiological mechanisms because it's probable that the other viral hemorrhagic fevers possess comparable pathways.

Significant strides have been taken in the creation of quick and early YF diagnostic techniques, allowing for efficient disease surveillance. For many years, laboratory-based vigilance has been used in some nations in conjunction with proactive control measures. Improved diagnostic techniques will likely be used more frequently over the next ten years in endemic areas, allowing for early intervention and the avoidance of widespread epidemics. The vaccination of people living in endemic regions of Africa will persist, and additional African nations will incorporate the YF 17D vaccine into their regular baby immunization programs.

Chapter 6
Conclusion

6.1 Conclusion:

Despite the existence of a highly efficient vaccine, yellow fever remains a serious threat to public health due to its recurrent outbreaks and growth into new regions. A high level of international migration and population movement increases the danger of outbreaks because the virus can be brought into highly populated urban regions that really are home to mosquitoes that can spread the disease. Inadequate vaccine supplies have been a significant barrier to reducing the spread of yellow fever, although coordinated efforts, supported by adequate funding, moral will, and leadership, can assist overcome this difficulty. While it is currently impossible to eradicate the YF virus from animal reservoirs, there are methods available to do it in humans. Focus should be placed on enhancing epidemic response, expanding access to immunization, and enhancing vector control procedures. In addition, continuing investigations into the causes of yellow fever as well as the creation of novel treatments and vaccines offer hope for improved disease prevention and management. A concerted and persistent effort will be needed from the whole worldwide health sector, including decision-makers, researchers, medical professionals, and the general public, to successfully manage yellow fever. We should work forward into a future when yellow fever is just no longer a significant hazard to public health by sustaining our cooperation and investment.

Chapter 7
Reference

7.1 Reference

7.1 Reference:

[1] Staples, J.E.; Monath, T.P. Yellow fever: 100 years of discovery. *JAMA* **2008**, *300*, 960–962. [CrossRef] [PubMed]

[2] Monath, T.P., Cetron, M.S., Teuwen, D.E., 2008. Yellow fever, in: Plotkin S,Orenstein W (Eds.), Vaccines, 5th ed., Saunders, Philadelphia, in press

[3] https://www.healthline.com/health/yellow-fever

[4] Wilder-Smith, A. et al. Epidemic arboviral diseases: priorities for research and

public health. Lancet Infect. Dis. 17, e101–e106 (2017).

[5] Barrett, A. D. & Higgs, S. Yellow fever: a disease that has yet to be conquered.

Annu Rev. Entomol. 52, 209–229 (2007).

[6] Wasserman, S., Tambyah, P. A. & Lim, P. L. Yellow fever cases in Asia: primed

for an epidemic. Int J. Infect. Dis. 48, 98–103 (2016).

[7] Black, W. C. 4th et al. Flavivirus susceptibility in Aedes aegypti. Arch. Med.Res. 33, 379–388 (2002).

[8] Mutebi, J. P. & Barrett, A. D. The epidemiology of yellow fever in Africa.

Microbes Infect. 4, 1459–1468 (2002).

[9] Saron, W. A. A. et al. Flavivirus serocomplex cross-reactive immunity is

protective by activating heterologous memory CD4 T cells. Sci. Adv. 4,

eaar4297 (2018).

[10] Hawley, W. A. The biology of Aedes albopictus. J. Am. Mosq. Control Assoc.

Suppl. 1, 1–39 (1988).

[11] Monath, T. P. (2008). Yellow fever: an update. The Lancet infectious diseases, 8(6), 365-374. doi: 10.1016/S1473-3099(08)70075-1

[12] Barrett AD, Monath TP. Epidemiology and ecology of yellow fever virus. Adv

Virus Res 2003;61:291–315.

[13] Carter HR. 1931. *Yellow Fever: An Epidemiological and Historical Study of Its Place of Origin*.Baltimore, MD:Williams &Wilkins.

[14] Tomlinson W, Hodgson RS. Centennial year of yellow fever eradication in New Orleans and the United States, 1905–2005. La State Med Soc 2005;157(2):216–7.

[15] JAMA. 1993 Sep 1;270(9):1071-5. Yellow fever in Philadelphia--the epidemic of 1793

[16] Vasconcellos, F. (2008). The History of Yellow Fever in Brazil. The Yale journal of biology and medicine, 81(4), 193–198.

[17] Marr, J. S. (2019). The history of yellow fever. In Mayo Clinic Proceeding (Vol. 94, No. 8, pp. 1461-1469).Elsevier. https://doi.org/10.1016/j.mayocp.2019.01.014.

[18] Morens, D. M., & Fauci, A. S. (2008). Dengue and hemorrhagic fever: A potential threat to public health in the United States. Jama, 299(2), 214-216. doi:10.1001/jama.2007.31

[19] World Health Organization. (2016). Yellow fever – China. Disease outbreak news, 13 May 2016. https://www.who.int/csr/don/13-may-2016-yellow-fever-china/en/

[20] Pan American Health Organization. (2018). Yellow fever in the Americas: Summary of cases and deaths in 2017. Retrieved from https://www.paho.org/hq/dmdocuments/2018/2018-jun-19-phe-yellow-fever-americas-2017.pdf

[21] Monath TP. Yellow fever: an update. Lancet Infect Dis 2001;1(1):11–20.

[22] [1]"Africa Map," 2019. https://www.cdc.gov/yellowfever/maps/africa.html

[23] World Health Organization. Prevention and control of yellow fever in Africa, Geneva: WHO,1986.

[24] Tomori O. Impact of yellow fever on the developing world. *Adv Virus Res* 1999; **53:** 5–34.

[25] Durieux C. Mass yellow fever vaccination in French Africa south of the Sahara, In: Smithburn KC, Durieux C, Koerber R., et al. Eds. Yellow Fever Vaccination, pp. 115–21. Geneva: WHO,1956

[26] Monath TP. Yellow Fever: Victor, Victoria? Conqueror, Conquest? Epidemics and research in the last forty years and prospects for the future. *Am J Trop Med Hyg* 1991; **45:** 1–43.

[27] Tapsoba L, Tomori O, Okwo Bele J-M, et al. Strategies for prevention and control of yellow fever. In: Gessner BA, Fletcher M, Parent du, Chelet I, et al., Eds. Proceedings of the Fifth International Seminar on Immunization In Africa. Lyon: Foundation Marcel Merieux, pp. 98–9, 1996.

[28] Tomori O, Tapsoba L, Ndikuyeze A, et al. Controlling yellow fever in Africa by the year 2010.In: Gessner BA, Fletcher M, Parent du Chelet I, et al., Eds. Proceedings of the Fifth International Seminar on Immunization In Africa. Lyon: Foundation Marcel Merieux, pp. 183–86.1996.

[29] World Health Organization. Yellow fever vaccinations near one million mark in Liberia. Geneva,Switzerland: World Health Organization; February 9, 1996. Press release WHO/9.

[30] Nájera P, Oliva O, Vilca LM, Uriona S, Brathwaite O, Aldighieri S. YF risk mapping:methodology and results for the Americas. PAHO\HSD\IR viral diseases; 2013[unpublished information].

[31] Maurice J. 1993. Yellow fever makes a comeback. *Suom. Laakaril*. 48:3057-61.

[32] "Yellow Fever Endemic Zones in South America – Mapping Globalization." https://commons.princeton.edu/mg/yellow-fever-endemic-zones-in-south-america/ (accessed Feb. 22, 2023).

[33] Pan American Health Organization. Isolation of dengue type 3 virus prompts concern and action. Bull Pan Am Health Organ. 1995;29:184-185.

[34] World Health Organization. Dengue in the Americas: update. Wkly Epidemiol Rec. 1995;70:333-334.

[35] Cardoso JC, Almeida MAB, Santos E, et al. Yellow fever virus isolation from Haemagogus leucocelaenus and Aedes serratus mosquitoes: southern Brazil,2008. Emerg Infect Dis 2010;16(12):1918–24.

[36] Romano AP, Csta ZA, Ramos DG. Yellow fever outbreaks in unvaccinated populations, Brazil, 2008–2009. PLoS Negl Trop Dis 2014;8(3):e2740,http://dx.doi.org/10.1371/journal.pntd0002740.

[37] WHO. Yellow Fever 1996–1997 Part 1 *Wkly Epidemiol Rec* 1998; **73:** 354–9.

[38] CDC. Fatal yellow fever in a traveller returning from Venezuela, 1999. *MMWR Recomm Ref*2000; **49:** 303–5

[39] Teichmann D, Grobusch MP,Wesselmann H, et al. A hemorrhagic fever from the Cote d'Ivoire *Lancet* 1999; **354:** 1608.

[40] WHO. Communicable Disease Surveillance and Response—Imported yellow fever case in the Netherlands February 2000.

[41] Colebunders R, Mariage JL, Coche JC, et al. A Belgian traveller who acquired yellow fever in the Gambia *Clin Infect Dis* 2002; **35:** e113–6.

[42] Monath TP, Heinz FX. Flaviviruses In: Fields BN, Knipes DM, Howley PM, et al. eds. Fields Virology. 3rd ed, pp. 961–1034. Philadelphia: Lippincott-Raven Publishers, 1995.

[43] Monath TP, Yellow Fever: An update. *Lancet Infect Dis* 2001; **1:** 11–20.

[44] World Health Organization. Prevention and control of yellow fever in Africa, Geneva: WHO,1986.

[45] Chambers TJ, McCourt DW, Rice CM. Production of yellow fever virus proteins in infected cells: identification of discrete polyprotein species and analysis of cleavage kinetics using region-specific polyclonal antisera. Virology 1990;177(1):159–74.

[46] Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 1043–125.

[47] Rice CM, Lenches EM, Eddy SR, et al. Nucleotide sequence of yellow fevervirus: implications for flavivirus gene expression and evolution. Science 1985;229(4715):726–33.

[48] Brinton MA, Fernandez AV, Dispoto JH. The 30-nucleotides of flavivirus genomic RNA form a conserved secondary structure. Virology 1986;153(1):113–21.

[49] "Yellow fever virus (YFV) Overview: Overview, Symptoms, Transmission, Diagnosis, etc," *CUSABIO*. https://www.cusabio.com/infectious-diseases/yellow-fever-virus.html.

[50] Fernandez-Garcia MD, Mazzon M, Jacobs M, et al. Pathogenesis of flavivirus

infections: using and abusing the host cell. Cell Host Microbe 2009;5(4):318–28.

[51] "Yellow fever virus (YFV) Overview: Overview, Symptoms, Transmission, Diagnosis, etc," *CUSABIO*. https://www.cusabio.com/infectious-diseases/yellow-fever-virus.html.

[52] Bressanelli S, Stiasny K, Allison SL, et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J2004;23(4):728–38.

[53] Modis Y, Ogata S, Clements D, et al. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004;427(6972):313–9.

[54] Brinton MA, Dispoto JH. Sequence and secondary structure analysis of the 50-terminal region of flavivirus genome RNA. Virology 1988;162(2):290–9.

[55] Edgil D, Polacek C, Harris E. Dengue virus utilizes a novel strategy for translation initiation when cap-dependent translation is inhibited. J Virol 2006;80(6):2976–86.

[56] Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res 2003;59:23–61.

[57] Lorenz IC, Kartenbeck J, Mezzacasa A, et al. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol 2003;77(7):4370–82.

[58] Mackenzie JM, Westaway EG. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 2001;75(22):10787–99.

[59] Hase T, Summers PL, Eckels KH, et al. An electron and immunoelectron microscopic study of dengue-2 virus infection of cultured mosquito cells: maturation events. Arch Virol 1987;92:273–9.

[60] Guirakhoo F, Heinz FX, Mandl CW, et al. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions.J Gen Virol 1991;72(Pt 6):1323–9.

[61] Yu IM, Zhang W, Holdaway HA, et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008;319:1834–7.

[62] Li L, Lok SM, Yu IM, et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008;319(5871):1830–4.

[63] Monath TP. Facing up to re-emergence of urban yellow fever. Lancet 1999;353(9164):1541.

[64] Johansson, M.A.; Arana-Vizcarrondo, N.; Biggerstaff, B.J.; Gallagher, N.; Marano, N.; Staples, J.E. Assessing the risk of international spread of yellow fever virus: A mathematical analysis of an urban outbreak in Asuncion, 2008. *Am. J. Trop. Med.* **2012**, *86*,349–358. [CrossRef]

[65] Couto-Lima, D.; Madec, Y.; Bersot, M.I.; Campos, S.S.; Motta, M.A.; Santos, F.B.D.; Vazeille, M.; Vasconcelos, P.; Lourenço-de-Oliveira, R.; Failloux, A.B. Potential risk of re-emergence of urban transmission of yellow fever virus in Brazil facilitated by competent aedes populations. *Sci. Rep.* **2017**, *7*, 4848. [CrossRef]

[66] Germain M, Francy DB, Monath TP, Ferrara L, Bryan J, et al. 1981. Yellow fever in Gambia, 1978–1979: entomological aspects and epidemiological correlations. *Am. J.Trop.Med. Hyg.* 29:929–40.

[67] Mutebi JP, Barrett ADT. 2002. The epidemiology of yellow fever in Africa. *Microbes Infect*. 4:1459–68

[68] Simon, L.V.; Hashmi, M.F.; Torp, K.D. *Yellow Fever*; Stat Pearls Publishing: Treasure Island, FL, USA, 2021.

[69] Monath, T.P. Facing up to re-emergence of urban yellow fever. *Lancet* **1999**, *353*, 1541. [CrossRef]

[70] "Yellow fever virus (YFV) Overview: Overview, Symptoms, Transmission, Diagnosis, etc," *CUSABIO*. https://www.cusabio.com/infectious-diseases/yellow-fever-virus.html

[71] Monath TP, Yellow Fever: An update. *Lancet Infect Dis* 2001; **1:** 11–20.

[72] Klotz O, Belt TH. The pathology of the liver in yellow fever. Am J Pathol1930;6:663–88.

[73] Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 1043–125.

[74] De Brito T, Siqueira SA, Santos RT, et al. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. Pathol Res Pract 1992;188(1-2):177–81.

[75] Quaresma JA, Barros VL, Pagliari C, et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNFalpha and NK cells activity. Virology 2006;345(1):22–30.

[76] Monath TP, Brinker KR, Chandler FW, et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever. *Am J Trop Med Hyg* 1981; **30:** 431–41.

[77] ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patientswith yellow fever. J Infect Dis 2004;190(10):1821–7.

[78] Khaiboullina SF, Rizvanov AA, Holbrook MR, et al. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology 2005;342(2):167–76.

[79] Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 2003;60:343–95.

[80] Johansson MA, Vasconcelos PFC, Staples JE. The whole iceberg : estimating

the incidence of yellow fever virus infection from the number of severe cases. Trans R Soc Trop Med Hyg. 2014;108:482–7.

[81] CDC. (2019). Symptoms, Diagnosis, & Treatment. Retrieved from Centers for Disease Control and Prevention website: https://www.cdc.gov/yellowfever /symptoms/index.html.

[82] Pettit, A., Stefanopoulo, G.J., Frasey, G., 1928. Serum anti-amaryllique. Compt. Rend. Soc. Biol. 99, 541–548.

[83] Colebunders, R., Mariage, J.-L., Coche, J.-C., et al., 2002. A Belgian traveler who acquired yellow fever in the Gambia. Clin. Infect. Dis. 35, 113–116.

[84] Tam, R.C., Lau, J.Y., Hong, Z., 2003. Antivir. Chem. Chemother. 12,260–272.

[85 Gabrielsen, B.J., Kirsi, J.J., Kwong, C.D., et al., 1994. In vitro and in vivo antiviral (RNA) evaluation of orotidine 5_-monophosphate decarboxylase inhibitors and analagoues including 6-azauridine-5_-(ethyl methoxyalaniyl) phosphate (a 5_-monopjhosphate prodrug). Antivir. Chem.Chemother. 5, 209–220.

[86] Gu, B., Mason, P.,Wang, L., et al., 2007. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus,West Nile virus, dengue virus and hepatitis B virus. Antivir. Chem. Chemother. 18, 49–59.

[87] Puig-Basaqoiti, F., Tilghner, M., Forschev, B.M., et al., 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50, 1320–1329.

[88] Chu, J.J., Yang, P.L., 2007. c-Src protein kinase inhibitors block assembly

and maturation of dengue virus. Proc. Natl. Acad. Sci. (USA) 104,3520-3505

[89] Robertson SE. Yellow Fever: The immunological basis for immunization, Geneva: WHO, 1993.

[90] Durieux, C. Preparation of yellow fever vaccine at the Institut Pasteur, Dakar, In: Smithburn KC, Durieux C, Koerber R, et al., Eds. Yellow Fever Vaccination. Pp 31–2, Geneva: WHO,1956.

[91] Durieux C. Mass yellow fever vaccination in French Africa south of the Sahara, In: Smithburn KC, Durieux C, Koerber R., et al. Eds. Yellow Fever Vaccination, pp. 115–21. Geneva: WHO,1956.

[92] Theiler M. Smith HH. Use of yellow fever modified by an in vitro cultivation for human immunization. *J Exp Med* 1937; **29:** 62–4

[93] Theiler M. The development of vaccines against yellow fever—Les Prix Nobel de 1951. In: Collected papers by members of the staff of the Division of Medicine and Public Health of the Rockefeller Foundation. New York: Rockefeller Foundation, 1952.

[94] Barrett ADT. Yellow fever vaccines. *Biologicals* 1997; **25:** 17–25.

[95] Monath TP. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, eds.Vaccines. 4th ed. Philadelphia: WB Saunders, **2004**:1095–176.

[96] Barrett, A.D.T. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. Vaccine **2017**, 35, 5951–5955. [CrossRef] [PubMed]

[97] Beck, A.S.; Barrett, A.D. Current status and future prospects of yellow fever vaccines. Expert Rev. Vaccines **2015**, 14, 1479–1492.[CrossRef] [PubMed]

[98] Lang, J.; Zuckerman, J.; Clarke, P.; Barrett, P.; Kirkpatrick, C.; Blondeau, C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am. J. Trop. Med. Hyg. **1999**, 60, 1045–1050. [CrossRef]

[99] Belmusto-Worn, V.E.; Sanchez, J.L.; McCarthy, K.; Nichols, R.; Bautista, C.T.; Magill, A.J.; Pastor-Cauna, G.; Echevarria, C.; Laguna- Torres, V.A.; Samame, B.K.; et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am. J.Trop. Med. Hyg. **2005**, 72, 189–197. [CrossRef]

[100] Juan-Giner, A.; Kimathi, D.; Grantz, K.H.; Hamaluba, M.; Kazooba, P.; Njuguna, P.; Fall, G.; Dia, M.; Bob, N.S.; Monath, T.P.; et al.Immunogenicity and safety of fractional doses of yellow fever vaccines: A randomised, double-blind, non-inferiority trial. Lancet **2021**, 397, 119–127. [CrossRef]

[101] WHO. Vaccines and vaccination against yellow fever. WHO position paper –June 2013. Wkly Epidemiol Rec. 2013;88(27):269–83.

[102] Staples JE, Bocchini JA Jr, Rubin L, Fischer M. Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses:recommendations of the advisory committee on immunization practices,2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647–50.

[103] Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434–44.

[104] Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014; 32:4977–84.

[105] Vasconcelos PFC, Barrett ADT. Are booster doses of yellow fever vaccine needed? Lancet Infect Dis. 2019. https://doi.org/10.1016/S1473-3099(19)30411-6 [Epub ahead of print].

[106] Group for Studies of Yellow Fever Vaccine. A randomized double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015;110:771–80.

[107] Goujon C, Gougeon ML, Tondeur L, Poirier B, Seffer V, Desprès P, et al. CHRONOVAC VOYAGEUR: a study of the immune response to yellow fever vaccine among infants previously immunized against measles. Vaccine. 2017;35(45):6166–71.

[108] Domingo C, Fraissinet J, Ansah PO, Kelly C, Bhat N, Sow SO, Mejía JE. Longterm immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study. Lancet Infect Dis. 2019;19(12):1363–70.

[109] Kareko BW, Booty BL, Nix CD, Lyski ZL, Slifka MK, Amanna IJ, Messer WB.Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting. J Infect Dis. 2019. https:// doi.org/10.1093/infdis/jiz374 [Epub ahead of print].

[110] Monath TP, GershmanM, Staples JE, Barrett ADT. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA (eds.) *Vaccines*, 6th edn. Philadelphia, PA: Saunders Elsevier, 2013, pp.870–968.

[111] Staples JE, Gershman MD, Fischer M. Recommendations of the Advisory Committee on Immunization Practices (ACIP): yellow fever vaccine. *MMWR Morb Mortal Wkly Rep* 2010;**59**(RR-7): 1–27.

[112] Chen, L., et al. (2018). NK cell-based immunotherapy for viral diseases. Advances in Experimental Medicine and Biology, 1045, 383-400. https://doi.org/10.1007/978-981-10-7230-7_25

[113] Monath TP, GershmanM, Staples JE, Barrett ADT. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA (eds.) *Vaccines*, 6th edn. Philadelphia, PA: Saunders Elsevier, 2013, pp.870–968.

[114] Monath TP, Gershman M, Staples EJ, Barrett ADT. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Saunders Elsevier;

2012. p. 870–96 [chapter 36].

[115] Monath TP, Fowler E, Johnson CT, et al. A clinical trial of an inactivated, cell.